Sisram Medical Ltd ("Sisram" or the "Company"; stock code: 1696.HK), a leading global provider of energy-based medical aesthetic treatment systems, today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong, S.A.R., China Limited ("SEHK"). The Company will be the first Israeli company to get listed in Hong Kong, S.A.R., China.
Sisram plans to offer an aggregate of 110,000,000 shares (subject to the over-allotment option), consisting of 99,000,000 international offer shares (subject to reallocation and the over-allotment option) and 11,000,000 Hong Kong, S.A.R., China offer shares (subject to reallocation), at an indicative offer price range between HK$8.88 and HK$12.35 per share. The listing of Sisram constitutes a spin-off of the Company from Fosun International Limited ("Fosun International") and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"). Of the 99,000,000 offer shares initially being offered under the international offering, 5,500,000 offer shares will be offered to qualifying shareholders of Fosun International pursuant to the preferential offering.
The Hong Kong, S.A.R., China public offering opened at 9:00 a.m. on Tuesday, 5 September 2017 and will close at 12:00 noon on Friday, 8 September 2017 in Hong Kong, S.A.R., China. Dealings in shares on SEHK are expected to commence on Tuesday, 19 September 2017, with the stock code 1696.HK in board lots of 400 shares each.
Shanghai Free Trade Zone Phase I Equity Investment Fund Partnership Enterprise (Limited Partnership), Rise Huge Corporation Limited and Neo Derm Group Limited are the cornerstone investors. China International Capital Corporation Hong Kong, S.A.R., China Securities Limited and Jefferies Hong Kong, S.A.R., China Limited (in alphabetical order) are the joint sponsors, joint global coordinators, joint bookrunners and joint lead managers. Fosun Hani Securities Limited is the joint global coordinator, joint bookrunner and joint lead manager. Haitong International Securities Company Limited and Huatai Financial Holdings (Hong Kong, S.A.R., China) Limited are the joint bookrunners and joint lead managers. China International Capital Corporation Hong Kong, S.A.R., China Securities Limited is the sole settlement agent and sole stabilizing manager.
The largest provider of energy-based medical aesthetic treatment systems in the PRC and the fifth in the energy-based medical aesthetic treatment system market globally
Sisram is the largest provider of energy-based medical aesthetic treatment systems in the PRC. According to the Medical Insight Report, Sisram was ranked fifth globally in 2016 in terms of revenue derived from sales of energy-based medical aesthetic treatment systems. Taking advantage of the global growth in the market of energy-based medical aesthetic treatment systems and an overall increase in discretionary income globally, the Company, as the leader in the aesthetic medical treatment system market, expected to continue capitalizing on the growth of this market by cooperation with the Controlling Shareholder, Fosun Pharma. Besides, the Company also develops energy-based minimally invasive treatment system market segment, embracing the rapid growth in global energy-based vaginal rejuvenation treatment system. Sisram Medical was incorporated in 2013 when Fosun Pharma acquired Alma Lasers Ltd. ("Alma"). Today, Alma is a wholly-owned and principal operating subsidiary of Sisram. Broad technology platform and comprehensive product offerings with a wide range of applications has enabled the Company to meet the diverse and specific needs of various treatment providers and their treatment recipients.
Strong R&D capability laid a solid foundation to continue launching a wide r...
(All Rights Reserved)